Reporting a falsified product to EMA
HumanCompliance and inspections
Marketing and manufacturing authorisation holders should report any falsified centrally authorised medicine to the European Medicines Agency (EMA), including a suspected falsified medicine, following the instructions provided.
For general information on falsified medicines and reporting obligations, see Falsified medicines: reporting obligations.
Complete the falsified medicinal product report template and submit to qdefect@ema.europa.eu:
Note: This form needs to be opened with a PDF reader. EMA advises to save the document first, and then open with a PDF reader, such as Acrobat Reader.
For guidance on using the template, see:
You should receive an acknowledgement in one working day during EMA business hours. If you do not, you can phone EMA on:
Outside of EMA business hours, use the following urgent contact number:
Provide the authenticity testing report, describing whether the falsification is confirmed or not.
For a confirmed falsification, provide details of the discrepancies in relation to the authentic product (for example, the outer labelling or content).
If these final reports are not available when notifying EMA, provide interim reports, as requested by EMA.
Parallel distributors notifying EMA of a suspected falsified medicine before informing the marketing authorisation holder should also liaise directly with the marketing authorisation holder and provide a sample of the suspicious unit for authenticity testing.
Keep EMA immediately informed of any changes or additional information.